Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?
ESMO 2024: Cora Sternberg video interview about her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer.
This project received funding from the European Research Council (ERC) and from the Samuel and Barbara Sternberg Foundation.
The INSIDE-PC study provides evidence of the potential of AI systems in medical literature searches on complex clinical questions.
ESMO Congress 2024 - European Society for Medical Oncology Barcellona 13-17 Settembre 2024
In this video Cora Sternberg talks about efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel by disease, volume and risk in the phase three Arasens study.
In this video Dr. Cora Sternberg discusses new developments in the treatment of urothelial carcinoma.
In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of prostate cancer.
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy.
Exploration of therapeutic vulnerabilities exposed by 9p21 loss in bladder cancer cell lines.
Dr. Cora Sternberg lecture: Precision medicine for prostate cancer
Balance sheets
Precision medicine is an emerging approach to the treatment and prevention of diseases that takes into account the individual variability of each person's genes, environment and lifestyle.
The Samuel and Barbara Research Foundation call for applications is open year long. Fellowships are available to those working in Italy in the field of Cancer research or related to cancer research.
Reporting
In the EU, 1,269,200 cancer deaths are expected in 2022; the corresponding age-standardized rates (world) fall by 6% to 126.9 deaths/100,000 in men and by 4% to 80.2/100,000 in women since 2017.
A panel discussion, moderated by Vadim Koshkin, MD, of the University of California, San Francisco, features Dr. Cora Sternberg.
Company documents
Dr. Cora Sternberg is an American oncologist who trained at the Memorial Sloan Kettering Cancer Center in New York and was the Chief of Medical Oncology in one of Italy’s largest public hospitals in Rome.
Medical Oncology is a science in rapid evolution. We are witnessing every day important developments in molecular medicine that clearly have positive impacts on improving cancer treatments.
Urology is one of the specialist surgical branches that has evolved the most in the last twenty years, with continuous and very important innovations in diagnostic-therapeutic terms.
Dr. Cora Sternberg explains the importance of research to find personalized therapies and drugs in the treatment of tumors.
Dr. Cora Sternberg discusses adjuvant therapy for muscle-invasive bladder cancer: new therapies and new standards of care.
Latest studies and updates on prostate cancer, including PROpel, MAGNITUDE and the ARCHES study.
Interview with Dr. Cora Sternberg, Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York - Presbyterian
Interview with Dr. Cora Sternberg about types of treatment for advanced bladder cancer.
Metastatic castration-resistant prostate cancer (CRPC) is a form of prostate cancer that becomes resistant to treatment with hormone therapy. In this case, the hormonal drug no longer provides benefits and other therapeutic options are necessary.
Interview with Dr. Cora Sternberg about clinical trials and new research on metastatic castration-resistant prostate cancer.
Clinical study on advanced bladder cancer.
Dr. Cora Sternberg discusses data from the Card study in patients with metastatic castration-resistant prostate cancer (mCRPC)
Dr. Sternberg talks about the Prosper study and prostate cancer treatments.
Advanced bladder cancer: Dr. Cora Sternberg talks about advances in recent years and new therapies.
Important results from the Card study for metastatic prostate cancer.
mCRPC, interview with Dr. Cora Sternberg
Dr. Cora Sternberg discusses the results of important studies for bladder cancer
Important results of the ARAMIS Trial, PROSPER Trial and SPARTAN TRIAL for prostate cancer, commented in this interview by Dr. Cora Sternberg.
Dr. Sternberg discusses the results of clinical trials in kidney cancer and bladder cancer.
Dr. Cora Sternberg first talks about urothelial cancer, and the Keynote-45 study on immunotherapy: some data on quality of life, they are really important.
The Samuel and Barbara Sternberg Cancer Research Foundation ETS is proud to have a scientific advisory board composed of the world's leading oncologists.
04 Jun
28 Nov
06 Oct
12 Sep
13 Jul
12 Jul
27 May
27 May
02 Jen
04 Dec
27 Oct
11 Oct
10 Oct
05 Jul
22 Jun
06 Jun
02 Jun
16 May
03 May
03 May
06 Apr
05 Apr
04 Apr
03 Apr
02 Apr
01 Apr
29 Mar
28 Mar
25 Mar
24 Mar
23 Mar
22 Mar
21 Mar
20 Mar
18 Mar
16 Mar
14 Mar
10 Mar
04 Dec